Nothing said here yet.
to join the conversation.
BOSTON, October 30, 2026--PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
BOSTON, October 29, 2026--PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
BOSTON, October 26, 2026--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026
BOSTON, October 19, 2026--PureTech Announces Presentation of Phase 1b Results for LYT-200 in R/R High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia at ESMO 2026
BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress
BOSTON, October 07, 2026--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) is undervalued ahead of potential shareholder cash returns, according to Panmure Liberum, which initiated coverage with a ‘buy’ rating and a 200 pence target.
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on…
BOSTON, September 21, 2026--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the successful completion of the End-of-Phase 1 (EOP1) meeting with the U.S.